Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Affinity Label

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Affinity Label. Displaying page 1 of 1.
    EudraCT Number: 2020-004176-18 Sponsor Protocol Number: CHK01-02 Start Date*: 2021-06-21
    Sponsor Name:Chinook Therapeutics U.S., Inc.
    Full Title: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
    Medical condition: Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g) Focal segmental glomerulosclerosis (FSGS) Alport Syndrome Diabetes kidney disease (DKD) (...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000148-76 Sponsor Protocol Number: 3.0 Start Date*: 2021-08-04
    Sponsor Name:Stockholm Health Care Services
    Full Title: Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial.
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000253-36 Sponsor Protocol Number: CD-IA-MEDI-551-1155 Start Date*: 2014-12-08
    Sponsor Name:MedImmune LLC
    Full Title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disord...
    Medical condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018780-42 Sponsor Protocol Number: OMB113676 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
    Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000893-69 Sponsor Protocol Number: BN42082 Start Date*: 2020-10-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS
    Medical condition: Relapsing Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003528-33 Sponsor Protocol Number: VIB0551.P2.S2.NMO Start Date*: 2022-04-13
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder
    Medical condition: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000894-26 Sponsor Protocol Number: BN42083 Start Date*: 2020-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL...
    Medical condition: Primary Progressive Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002008-11 Sponsor Protocol Number: IMC-M113V-103 Start Date*: 2021-11-24
    Sponsor Name:Immunocore Limited
    Full Title: An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01-positive subjects with chronic HIV infection who are virologically sup...
    Medical condition: Chronic HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000826-22 Sponsor Protocol Number: CBLZ945C12201 Start Date*: 2019-09-17
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m...
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001498-15 Sponsor Protocol Number: BP29360 Start Date*: 2014-08-29
    Sponsor Name:F. Hoffmann- La Roche Ltd.
    Full Title: OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HIST...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Completed) NL (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001790-23 Sponsor Protocol Number: GCT1047-01 Start Date*: 2021-09-27
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1047-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003400-24 Sponsor Protocol Number: I3Y-MC-JPBZ Start Date*: 2016-01-29
    Sponsor Name:Lilly S.A.
    Full Title: monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physic...
    Medical condition: Hormone receptor positive, HER2-positive advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 08 17:09:11 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA